AMGEN INC. $750,000,000 3.000% SENIOR NOTES DUE 2029 $1,000,000,000 3.350% SENIOR NOTES DUE 2032 $1,000,000,000 4.200% SENIOR NOTES DUE 2052 $1,250,000,000 4.400% SENIOR NOTES DUE 2062 Underwriting AgreementUnderwriting Agreement • February 22nd, 2022 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 3.000% Senior Notes due 2029 (the “2029 Notes”), $1,000,000,000 principal amount of its 3.350% Senior Notes due 2032 (the “2032 Notes”), $1,000,000,000 principal amount of its 4.200% Senior Notes due
